Health Care [ 8/12 ] | Biotechnology [ 34/74 ]
NASDAQ | Common Stock
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases.
Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 20, 25 | -0.76 Increased by +11.63% | -0.89 Increased by +14.61% |
| Oct 31, 24 | -1.56 Decreased by -27.87% | -1.05 Decreased by -48.57% |
| Aug 1, 24 | -1.02 Increased by +29.66% | -0.90 Decreased by -13.33% |
| May 2, 24 | -0.48 Increased by +54.72% | -1.05 Increased by +54.29% |
| Feb 22, 24 | -0.86 Decreased by -13.16% | -1.01 Increased by +14.85% |
| Nov 2, 23 | -1.22 Decreased by -193.85% | -1.21 Decreased by -0.83% |
| Aug 3, 23 | -1.45 Decreased by -150.00% | -1.20 Decreased by -20.83% |
| May 4, 23 | -1.06 Decreased by -127.53% | -0.87 Decreased by -21.84% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 11.28 M Decreased by -32.82% | -104.59 M Increased by +9.82% | Decreased by -927.37% Decreased by -34.24% |
| Sep 30, 24 | 2.38 M Increased by +158.08% | -213.72 M Decreased by -30.78% | Decreased by -8.98 K% Decreased by -325.19% |
| Jun 30, 24 | 3.08 M Increased by +124.17% | -138.38 M Increased by +28.95% | Decreased by -4.50 K% Decreased by -393.93% |
| Mar 31, 24 | 56.38 M Increased by +20.69% | -65.28 M Increased by +53.69% | Decreased by -115.79% Increased by +61.63% |
| Dec 31, 23 | 16.79 M Decreased by -22.96% | -115.97 M Decreased by -14.14% | Decreased by -690.85% Decreased by -48.15% |
| Sep 30, 23 | -4.10 M Decreased by -101.10% | -163.41 M Decreased by -193.21% | Increased by +3.99 K% Increased by +8.35 K% |
| Jun 30, 23 | -12.72 M Increased by +70.20% | -194.78 M Decreased by -154.63% | Increased by +1.53 K% Increased by +754.38% |
| Mar 31, 23 | 46.71 M Decreased by -96.20% | -140.96 M Decreased by -127.18% | Decreased by -301.76% Decreased by -815.63% |